Table 1 Clinical demographics of multiple sclerosis patients and healthy controls
Untreated MS (n = 35) | MS w/ IFN-β (n = 21) | HCs (n = 44) | p value | |||
|---|---|---|---|---|---|---|
Untreated MS vs. HCs | MS w/ IFN-β vs. HCs | Untreated MS vs. MS w/ IFN-β | ||||
Female, n (%) | 30 (85.7) | 15 (71.4) | 27 (61.4) | 0.023 | NS | NS |
Age at examination, years | 50.0 (37.0–59.0) | 45.0 (42.5–48.5) | 35.0 (32.3–43.8) | < 0.001 | < 0.001 | NS |
Age at disease onset, years | 31.0 (24.0–37.0) | 30.0 (24.0–34.0) | – | – | – | NS |
Disease duration at examination, years | 13.6 (7.80–20.9) | 15.4 (10.7–20.8) | – | – | – | NS |
Subtype (RRMS / SPMS / PPMS), n (%) | 26/6/3 (74.3/17.1/8.6) | 13/7/1 (61.9/33.3/4.8) | – | – | – | NS |
EDSS score at examination | 2.0 (1.0–4.5) | 3.0 (1.75–6.0) | – | – | – | NS |
MSSS at examination | 2.44 (0.38–6.46) | 2.93 (1.00–7.15) | – | – | – | NS |
Disease duration at IFN-β initiation, years | – | 6.58 (1.92–12.1) | – | – | – | – |
EDSS score at IFN-β initiation | – | 2.5 (1.75–5.25) | – | – | – | – |
MSSS at IFN-β initiation | – | 5.24 (2.38–7.56) | – | – | – | – |
Years of IFN-β treatment | – | 7.0 (5.0–10.0) | – | – | – | – |